Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

Daniel F. Hayes, J. A. Van Zyl, Anne Hacking, Louis Goedhals, W. R. Bezwoda, James A. Mailliard, Stephen E. Jones, Charles L. Vogel, Robert F. Berris, Irving Shemano, John Schoenfelder

Research output: Contribution to journalArticle

221 Scopus citations

Abstract

Purpose: To perform a randomized three-arm comparison of tamoxifen (TAM; 20 mg/d) and two separate doses of toremifene (TOR; 60 mg/d [TOR60] and 200 mg/d [TOR200]) in postmenopausal patients with hormone receptor-positive or - unknown metastatic breast cancer. Materials and Methods: Six hundred forty- eight patients with hormone receptor-positive or -unknown metastatic breast cancer were randomly assigned to receive TAM (n = 215), TOR60 (n = 221), or TOR200 (n = 212). Results: The combined response rates (by intent to treat) were as follows: TAM, 44%; TOR60, 50%; and TOR200, 48%. Complete and partial response rates were as follows: TAM, 19%; TOR60, 21%, and TOR200, 23% (not statistically different). Median times to progression and overall survival were not significantly different. Adverse events (lethal, serious but nonlethal, and important but non-life-threatening) were similar in all three arms, except that patients in the TOR200 arm had a statistically significantly increased rate of nausea (37% v 26% and 26% for TOR200, TAM, and TOR60, respectively; P = .027). Quality-of-life assessments were not different among the three arms. Conclusion: The activity, toxicity, and side effects of TOR in postmenopausal women with hormone receptor-positive or - unknown metastatic breast cancer are similar if not equivalent to those of TAM. We detected no clear evidence of a dose-response effect for TOR. TOR60 is an effective and safe agent for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer and can be considered an alternative to TAM as first-line treatment for such patients.

Original languageEnglish (US)
Pages (from-to)2556-2566
Number of pages11
JournalJournal of Clinical Oncology
Volume13
Issue number10
DOIs
StatePublished - Oct 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., Shemano, I., & Schoenfelder, J. (1995). Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. Journal of Clinical Oncology, 13(10), 2556-2566. https://doi.org/10.1200/JCO.1995.13.10.2556